JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
AMG-517 is an antagonist of TRPV1 channel with IC50 value of 1-2 nM [1].TRP1, transient receptor potential cation channel subfamily V member 1, is a subfamily of the transient receptor potential protein group and plays an important role in detecting and regulating body temperature or sensing pain. TRPV1 can be activated by diverse stimuli, including several ingredients of the inflammatory soup which leads to a painful, burning sensation. It is reported that TRPV1 channel may play a pivotal role in many diseases like SIRS [1] [2]. AMG-517 is a TRPV1 antagonist. When tested with stable CHO cell lines expressing TRPV1, treated with AMG-517 inhibited the activation of TRPV1 [1]. In C57BL/6 mice with SIRS induced by LPS, pretreatment with AMG-517 (210 µg/kg) markedly decreased the survival rate and increased the risk of mortality [2]. When tested with Trpv1-/- mice, intraperitoneally treated with AMG-517 (256 nmol/kg) inhibited TRPV1 with inducing hyperthermia in a dose-dependent manner [3]. In capsaicin-induced flinch male Sprague-Dawley rats, oral administration of AMG-517 markedly decreased the number of flinches in a dose-dependent manner [1].References: [1].Gavva, N.R., et al., Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade. J Pharmacol Exp Ther, 2007. 323(1): p. 128-37.[2].Wanner, S.P., et al., Aging reverses the role of the transient receptor potential vanilloid-1 channel in systemic inflammation from anti-inflammatory to proinflammatory. Cell Cycle, 2012. 11(2): p. 343-9.[3].Garami, A., et al., Contributions of different modes of TRPV1 activation to TRPV1 antagonist-induced hyperthermia. J Neurosci, 2010. 30(4): p. 1435-40.
Cell lines
CHO cells
Preparation method
The solubility of this compound in DMSO is > 21.5mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.
Reacting condition
1-2 nM
Applications
AMG 517 is a selective antagonist of both rat and human TRPV1 with dissociation constant values of 4.2 and 6.2 nM, respectively. AMG 517 effectively and completely inhibited capsaicin, proton, and heat activation of TRPV1 in vitro. AMG 517 potently inhibited capsaicin-, acid-, and heat-induced Ca2+ uptake into CHO cells expressing TRPV1 with IC50 values of 1 to 2 nM.
Clinical samples
Healthy adults
Dosage form
Oral administration, 2, 5 and 10 mg
Application
AMG 517 blocked TRPV1 and elicited a generally plasma concentration-dependent hyperthermia in healthy humans. AMG 517 caused hyperthermia by increasing thermogenesis and inducing tail skin vasoconstriction, indicating that TRPV1 regulates metabolic heat production and vasomotor tone in humans.
Other notes
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.
References:
[1]. Gavva N R, Bannon A W, Hovland D N, et al. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade[J]. Journal of Pharmacology and Experimental Therapeutics, 2007, 323(1): 128-137.
[2]. Gavva N R, Treanor J J S, Garami A, et al. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans[J]. Pain, 2008, 136(1): 202-210.
